NEW YORK, August 2, 2017 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, including the commercialization of Strontium Chloride 89, multiple IND enabling studies, CMC manufacturing and at least one IND filing.

Pursuant to the securities purchase agreement, accredited investors received 953,247 units with each unit consisting of one share of our common stock priced at $3.20 and a five-year warrant to purchase one additional share of our common stock at $4.50.

Denis Corin, CEO QBioMed Inc., said, “This capital provides the runway we need to meet some significant milestones over the next few months. We are eagerly anticipating Sr89 commercial production, which is in final QC and validation. Also the pre-IND work on QBM001 for the treatment of young children with a rare autistic spectrum disorder causing them to lose the ability to speak, is expected to be complete and a submission to the regulators for IND is expected before year end.”

Brookline Capital markets, a division of CIM Securities, LLC acted as the exclusive placement agent for the offering.

For more information, please refer to our Form 8K filed today.

Please visit our website http://www.qbiomed.com and follow us on social media @QBioMed to stay updated on our progress.

About Q BioMed, Inc. 

Q BioMed, Inc., (Q) is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need. 

Forward-Looking Statements: 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Dennis Corin
CEO, Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, October 5, 2017 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced today the launch of http://www.PainFreeCancer.com. This website is designed to provide a resource for patients, doctors and caregivers dealing with the severe pain associated with late stage cancer metastases to the bone.

U.S. Food and Drug Administration approved Generic Strontium Chloride Sr89 Injection, USP; (Strontium-89) is a Non-Opioid pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium-89 acts similar to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Up to 80% of patients report pain relief lasting for months.

Strontium Chloride Sr89 Injection, USP can be used in combination with other therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with Strontium-89 demonstrated a prolonged progression-free and overall survival in patients.

Visit http://www.PainFreeCancer.com today.

Strontium Chloride Sr89 Injection, USP Usage and Indications: 

Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis, thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Strontium-89 is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones. Strontium-89 is a pure beta emitter and Strontium-89 selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue is 8 mm; maximum energy is 1.463 MeV.) Clinical trials have examined relief of pain in cancer patients who have received therapy for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred.

INDICATIONS AND USAGE: Strontium-89 Chloride Injection is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.

CONTRAINDICATIONS: None known.

WARNINGS: Use of Strontium-89 (Sr89) in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected following the administration of Strontium-89, particularly white blood cells and platelets. The extent of toxicity is variable. It is recommended that the patient’s peripheral blood cell counts be monitored at least once every other week. Typically, platelets will be depressed by about 30% compared to pre-administration levels. The nadir of platelet depression in most patients is found between 12 and 16 weeks following administration of Sr89. White blood cells are usually depressed to a varying extent compared to pre-administration levels. Thereafter, recovery occurs slowly, typically reaching pre-administration levels six months after treatment unless the patient’s disease or additional therapy intervenes. In considering repeat administration of Sr89, the patient’s hematologic response to the initial dose, current platelet level and other evidence of marrow depletion should be carefully evaluated. Verification of dose and patient identification is necessary prior to administration because Sr89 delivers a relatively high dose of radioactivity. Sr89 may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

About Q BioMed Inc. 

Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.

To stay up-to-date with Q BioMed developments, please visit http://www.qbiomed.com and sign up for our news distribution.

For more information, please visit http://www.PainFreeCancer.com  

Forward-Looking Statements: 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, October 12, 2017 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced today that their funding partner Yorkville Advisors have agreed to extend the maturity date on the $2M balance of their convertible note by one year to November 30 2018.

Dens Corin, CEO of QBioMed Inc. said, “Our relationship with Yorkville Advisors and their team has been very positive. We are pleased that this deal has worked out well for them and us and we will continue to work with them to secure the best outcome for both them and the rest of our shareholders.”

On November 29, 2016, the Company entered into a securities purchase agreement with Yorkville Advisors to place Convertible Debentures (the “Debentures”), with a one-year term in the aggregate principal amount of $4,000,000. The Debentures bear interest at the rate of 5% per annum.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, October 19, 2017 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that it has successfully developed a new and proprietary analog of QBM-001 in partnership with Sphaera Pharma for its intended use in pediatric developmental nonverbal disorder.

The novel analog was selected from an array of candidates that Sphaera Pharma’s patented platform produced and QBM-001’s pharmacodynamics demonstrated the best improvement in safety without compromising efficacy.

“We are very pleased to have successfully reached our developmental milestone with great results thus far, putting us in position to help these young children as well as their parents and caregivers,” said Denis Corin, CEO of Q BioMed. “We are highly motivated to develop a drug and delivery system that will accommodate their very specific needs. As a result of meeting this milestone, we are now in a position to move QBM-001 into the clinic as quickly as possible.”

The complete panel of preclinical testing is scheduled to finish in January of 2018. In parallel, Q BioMed is pursuing cGMP manufacturing and regulatory filings in preparation for the IND.

The proprietary analog will also provide Q BioMed with a global composition of matter patent for QBM-001. This will ensure that QBioMed can pursue the abbreviated 505(b)2 regulatory pathway in the USA to hopefully provide toddlers benefit from QBM-001 as soon as possible.

About Pediatric Development Nonverbal Disorder 
There are approximately 20,000 new cases of pediatric developmental nonverbal disorder in the USA each year and a similar amount in Europe. The majority of the children are diagnosed as toddlers and fall within the autism and epilepsy spectrum disorders. Individually, the economic costs for toddlers that become non- or minimally verbal is ten million on average per person over their life. Collectively, an estimated 200 billion dollars is spent yearly on individuals who have become nonverbal in the USA. Not all individuals who become nonverbal will benefit from QBM-001, but testing from a trained specialists and blood tests, coupled with genetic testing can identify a targeted population that will have a higher likelihood of responding to treatment.

About Q BioMed Inc. 
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements: 
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact: 

Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, November 14, 2017 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO) congratulates our collaborative research partner and licensor, Mannin Research Inc., on receiving R&D funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to initiate work on a Tie2-activating biologic for the treatment of glaucoma. Q BioMed has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications. This new biologic would be an additional product to the Mannin Tie2 pipeline.

Mannin’s new biologic therapeutic was developed by Mannin’s CSO, Dr. Susan Quaggin and her laboratory. The biologic has the potential to treat several additional, vascular related diseases, such as acute kidney injury, and cardiorenal syndrome. “As our understanding about the Angiopoietin-Tie2 system grows, I am very excited about the clinical therapeutic possibilities,” said Dr. Quaggin.

In the project, Mannin research will conduct a proof-of-concept study to determine the efficacy of its novel, specific, and potent biologic therapeutic. The research is supported by the NRC IRAP and will assist in Mannin developing additional research capacity within Mannin.

The impact of novel therapeutics developed by Mannin has direct benefits to Canadian glaucoma patients and those suffering with glaucoma around the world. There is an acute need for better therapeutic solutions for the hundreds of thousands of people suffering from glaucoma and those yet to be diagnosed. The number of potential patients in this therapeutic area demanding better treatments make this a multi-billion-dollar opportunity.

It is anticipated, success in the biologic proof-of-concept project will enable Mannin to add to its R&D pipeline. Development of the MAN-01 small molecule for the treatment of primary open-angle glaucoma continues on-pace and is now at a point where the most active candidates will be selected for final testing and optimization as a soluble, topical eye drop that permeates well into the eye. It is anticipated that pre-clinical IND enabling studies will begin in Q2 2018.

About Mannin Inc.  

Mannin Research Inc is utilizing a proprietary research platform, this technology is addressing the need for a new class of drugs to treat various vascular diseases. Our lead indication is for a First-In-Class therapeutic eye drop for the treatment of Primary Open Angle Glaucoma. Mannin is developing a unique molecule in the form of an easy to administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of intra-ocular eye pressure (IOP), one of the main causes of Glaucoma. Mannin is the only company targeting this method of action. Mannin has a deep pipeline of novel therapeutics that can be developed from this research platform, which would treat a spectrum of vascular diseases including Cystic Kidney Disease, Pediatric Glaucoma, Cardiovascular Disease and Inflammation.

About Q BioMed Inc.  

Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements:  

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, November 28, 2017 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.

Dr. Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.

“We are honoured to have Dr. Helen Tager-Flusberg join our advisory committee for QBM-001. She is a pioneer in her field, working with autism spectrum disorders to design speech and language assessment measures to capture their progress,” said, Denis Corin, CEO of Q BioMed Inc.

Dr. Tager-Flusberg has dedicated much of her career to developing meaningful approaches to assess expressive language development in toddlers and children with developmental delay and autism spectrum disorders.

Her newest approach is called ELSA-T, which stands for Expressive Learning Sample Assessment for Toddlers. ELSA-T leverages validated components for language development, combined with more flexibility with the protocol to better adapt to the needs of a clinical trial and to the needs of caregivers and patients.

“Communication matters for all people,” said Dr. Helen Tager-Flusberg. “And for me, it is all the more inspiring to be able to help design language assessment tools, such as ELSA-T, to assess speech and language development for toddlers with pediatric developmental delay in the autism spectrum disorder.”

Q BioMed is preparing to use ELSA-T to capture language development as the primary endpoint for when toddlers are treated with QBM-001 in their planned clinical trial in 2018.

About Pediatric Development Nonverbal Disorder 

There are approximately 20,000 new cases of pediatric developmental nonverbal disorder in the USA each year and a similar amount in Europe. The majority of the children are diagnosed as toddlers and fall within the autism and epilepsy spectrum disorders. Individually, the economic costs for toddlers that become non- or minimally verbal is ten million on average per person over their life. Collectively, an estimated 200 billion dollars is spent yearly on individuals who have become nonverbal in the USA. Not all individuals who become nonverbal will benefit from QBM-001, but testing from a trained specialists and blood tests, coupled with genetic testing can identify a targeted population that will have a higher likelihood of responding to treatment.

About ELSA-T 

Eliciting Language Samples Activities for Toddlers or ELSA-T takes advantage of an approach that is widely used in the developmental psycholinguistic literature: the collection and analysis of natural language samples (NLS) which are recordings of the language production of an individual.  The specific elicitation context can vary: a play session, a conversation, a narrative; the communicative partner can also be open: a parent, clinician, teacher, peer, or researcher. The duration of the sample can be adjusted to the specific aims of a study, through a sample of 15 – 30 minutes offers more robust measurement. The specific location where data are collected can also be tailored: at home, school, clinic or lab. Thus, the flexibility associated with the collection of NLSs makes them especially suitable for clinical trials on children with autism spectrum disorders and other disorders.

Boston University Center for Autism Research Excellence (CARE) 

CARE’s primary mission is to advance scientific knowledge about the language and social communication impairments in autism/ASD and related disorders. We carry out studies on all ages using behavioral, brain, and cognitive measures. The goal is to understand the range of abilities, the developmental patterns, and the brain systems that may explain why people with autism have difficulties communicating with spoken language. Our research is aimed at developing new interventions that directly address the communication problems that we discover. For more information, visit:  https://www.bu.edu/autism/

About Q BioMed Inc. 

Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements: 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact: 

Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, Dec. 21, 2017 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to provide this year end update to its shareholders.

The Company ends 2017 with a full pipeline of assets advancing towards major milestones in 2018. The Company also ends the year with a clean balance sheet, having settled all outstanding debt and is poised for a very productive a catalyst-rich year in 2018.

We are pleased to provide a summary and an update on our pipeline assets below.

Strontium Chloride 89 Injection USP (Strontium-89)

Strontium-89 is a U.S. Food and Drug Administration approved drug for pain palliation in bone metastases, primarily from breast, prostate and lung cancers. Our product is the only FDA approved generic version of this radiopharmaceutical and is reimbursable by Medicare and private insurers. Strontium 89 is a pure beta emitting radiopharmaceutical. It is a chemical analog of calcium and for this reason, localizes in bone. There is a significant concentration at the site of active osteoblastic activity. This is the biochemical basis for its use in treating metastatic bone disease.

Strontium-89 shows prolonged retention in metastatic bone lesions with a biological half-life of 50 days, remaining up to 100 days after injection. Strontium-89 has been shown to decrease pain in patients with metastases. When Strontium-89 Chloride is used, pain palliation occurs in up to 80% of patients within 2 to 3 weeks after administration and lasts from 3 to 12 months, on average of about 6 months.

In the United States, of the estimated 450,000 individuals newly diagnosed with either breast or prostate cancer, one in three will develop bone metastases, a common cause of pain. These figures are expected to increase as the patient population ages.

Strontium-89 is a non-narcotic (non-opioid) cost effective means for the clinical management of debilitating cancer bone pain. There is a significant opportunity to market Strontium-89 as practitioners and caregivers are being encouraged to reexamine the use of opiates for treating patients in pain. The pain palliation market is estimated to be approximately $300 million annually. Clinical studies at leading medical centers around the world have demonstrated that patient survivals may be extended using Strontium-89 in combination with other agents. Additional therapeutic indications for Strontium 89 are possible, and we intend to pursue this objective in 2018.

We have experienced some delay in launching this drug due to the 2 major hurricanes impacting both of our manufacturing and logistical operations in Texas and Florida, but expect to have a new facility online for manufacturing by mid-January 2018 and pending FDA facility review, commercial sales shortly thereafter. This is expected to be major milestone as we ramp up commercial operations and head into the new year with near-term and long-term recurring revenues as well as the prospect of a significant market opportunity in broader therapeutic indications.

QBM 001 -  Addressing a Rare Pediatric Non-verbal Spectrum Disorder

Causes of non-verbal learning disorder have been linked to several complications that range from a specific mutated gene as with Fragile X Syndrome and Dravet Syndrome or autoimmunity, in which the body’s immune system attacks parts of the brain. Trauma, microbial infections and environmental factors have also been linked to non-verbal learning disorder. Ongoing research is helping to further explain the root cause of why children become non-verbal or minimally verbal.

Children born into families where there is a genetic history of autism or epileptic spectrum disorders or that have a sibling that has been diagnosed with an autistic or epileptic spectrum disorder have a much higher chance of becoming non-verbal.

More than 60,000 US children develop Autism Spectrum Disorders (“ASD”) every year, of whom 20,000 become non-verbal. A similar number of children with ASD symptoms in Europe develop pediatric non-verbal disorder each year.  No drugs are currently available to ameliorate this condition. In the United States, of the estimated 20,000 who become non- or minimally verbal and will require assisted living for the rest of their life. The lifetime cost of that care is estimated at $10 million per person.

Cognitive intervention is the only form of treatment that has shown to improve speech capability and social interaction; however, it has not been able to alleviate the lifetime burden of $10 million per person for cost of care. This is compounded by an additional $10 million during the lifespan of the person due to loss in productivity in addition to severe emotional strain for the child and the parents.

In light of the above, we are developing QBM-001 to be administered to a high-risk, target group of toddlers of 3 years or younger. We can identify these toddlers by blood markers, EEG testing and whole genome sequencing. A commonality that these toddlers share is faulty membrane channels, which was elucidated from retrospective genetic studies of nonverbal individuals. Faulty membrane channels can lead to many detrimental effects. We believe that QBM-001 acts as an allosteric regulator of these faulty channels in the brain to potentially alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disability of being non-verbal.

As there are no treatment options for these patients, we believe there is a significant economic opportunity to bring a drug to market in this indication. The active ingredient in QBM-001 is well known and has been approved by worldwide regulators for many years. Q BioMed produced an analog of the parent molecule that serves multiple purposes. One, it eliminates gastrointestinal problems of the parent molecule. Two, it allows for a more time-release of product and it provides a load capacity, which is designed to prevent over-administration. Three, the aforementioned characteristics of QBM-001 then allow for more sustained levels of product in the body over time which is ideal for a condition that requires long-term, prophylactic use. Due to the unique composition of the analog and the known safety and efficacy of the parent molecule, we intend to advance this drug through the 505(b)(2) pathway in a single phase 2/3 clinical trial that we intend to commence in 2018.

We have made great progress in assembling our technical team and in the development of the final drug analogue which is now finishing pre-clinical testing. Once complete in Q1 2018, we expect to file an IND and initiate a pivotal clinical trial. We have already met with several potential clinical sites, both in the US and Europe and all look forward to collaborating on this pioneering study. Given the potential for an accelerated clinical trial pathway, we see this as a very significant catalyst in 2018 which could yield interim phase 2 data prior to the end of the year.

UTTROSIDE-B  -  A New Chemotherapeutic for Liver Cancer

The only currently marketed drug for liver cancer is a tryosine kinase inhibitor antineoplastic agent, Sorafinib. Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis in liver cancer). It is a natural compound fractionated Saponin derived from the Solarim Nigrum plant. It is a small molecule that showed in early investigation to increase the cytotoxicity of a variety of liver cancer cell types and importantly to be up to ten times more potent than Sorafenib in pre-clinical studies. This potency motivated us to work with our partners to chemically synthesize the plant based molecule. Synthesis has progressed well in 2017, and we expect to have the final analogue ready for testing in Q1 2018. Once validated, we will prepare and submit an IND for a Phase one clinical trial to begin in late 2018.

MAN 01 -  A Platform Technology with an Initial Focus on Glaucoma

We are developing MAN 01 as a first-in-class therapeutic eye-drop for the treatment of Primary Open Angle Glaucoma.

MAN 01 targets the Schlemm’s canal and its role in regulating interocular eye pressure, one of the leading causes of glaucoma. No other glaucoma company is targeting the Schlemm’s canal, the main drainage pathway in the eye. This unique vessel is responsible for 70-90% of the fluid drainage in the eye.

We believe that a deep pipeline of novel therapeutics can be developed from this research platform, which would treat a spectrum of vascular diseases including cystic kidney disease, pediatric glaucoma and inflammation.

We are completing development work on optimal delivery and absorption of a small molecule delivered topically to treat patients with Primary Open Angle Glaucoma. We anticipate completing pre-clinical proof-of-concept development in 2018 and expect to initiate a clinical trial program in 2019.

We have made great progress in our short history and we look forward to another exciting and eventful year in 2018. Stay up to date and follow our progress by joining our mailing list at www.qbiomed.com.

 Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435

View original content:http://www.prnewswire.com/news-releases/q-biomed-provides-year-end-update-300574412.html

SOURCE Q BioMed Inc

NEW YORK, January 3, 2018 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin, Chief Executive Officer, will present at the Biotech Showcase(™) 2018 Conference to be held January 8 – 10, 2018 in San Francisco, California.

Details of QBioMed’s’ participation are as follows:

   
    Event:      Biotech Showcase(TM) 2018 Conference

    Date:       Tuesday, January 09, 2018
    Time:       4:00 p.m. Pacific Time
    Location:   Room: Franciscan - B (Ballroom Level)
                Hilton Hotel Union Square
                San Francisco

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year.

Now in its tenth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.

In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals.

About Q BioMed Inc. 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact: 

Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, January 30, 2018 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO) (“Q BioMed” or the “Company”), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company, together with warrants to purchase up to 1,711,875 shares of common stock of the Company, at a public offering price of $3.20 per share and associated warrant. Each warrant will have an exercise price of $3.20 and will expire five years from the date of issuance. The gross proceeds from the offering are expected to be approximately $5.5 million, before deducting placement agent fees and other estimated offering expenses.

Roth Capital Partners is acting as lead placement agent and CIM Securities is acting as co-lead placement agent for the offering.

The offering is expected to close on or about February 1, 2018, subject to the satisfaction of customary closing conditions.

The Company anticipates that the proceeds from the offering will provide Q BioMed the required capital to execute on several significant milestones in the first half of 2018 and beyond. These catalysts include;

• The commercialization of our licensed FDA approved drug, Strontium Chloride 89 (SR89), a non-opioid therapeutic drug for the treatment of skeletal pain associated with metastatic cancers.
• Initiating the planning and IND filing for a Phase 4 post-marketing study to expand the indication of the approved SR89, labeling it as chemotherapeutic (a cancer therapy) for skeletal metastases, significantly improving the revenue potential for the drug.
• The filing of an IND for a pivotal phase ll/lll clinical program to test the efficacy of QBM-001, a pro-drug for the treatment of young children with a rare autistic spectrum disorder that severely inhibits their ability to communicate.
• Continued R&D on the novel chemotherapeutic drug for liver cancer.
• Completion of optimization and pre-clinical testing of the first-in-class glaucoma drug Man-01 for the treatment of open angle glaucoma, a disease affecting more than 60,000,000 people around the world.

Denis Corin, Q BioMed Inc. CEO said, “2018 is a catalyst-rich year for us. We have several major milestones on the near horizon and this capital provides the means to get there. In addition, given that we settled all our convertible debt at the end last year, this cash will boost our shareholder equity, further progressing us towards an uplisting on a senior national exchange.”

Q Biomed is a commercial stage biomedical acceleration and development company. We spent our first two years building a valuable portfolio of assets that we believe have significant upside based on our investment in their development. This year, the return on that investment of strategic resources should start to be realized as we advance those assets along their important commercial paths towards the patients that need them and economically, the billion dollar markets they represent.

Please visit http://www.qbiomed.com for more information and sign up to receive regular updates. Follow us on social media @QBioMed.

More information on the funding can be found on our form 8k filed with the SEC today.

A registration statement on Form S-1 (File No. 333-222008) relating to this offering was declared effective by the Securities and Exchange Commission (SEC) on January 12, 2018. The securities may be offered only by means of a prospectus. A copy of the final prospectus is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus also may be obtained from Roth Capital Partners, LLC, Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, at 800-678-9147 and rothecm@roth.com .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Q BioMed, Inc. 
Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements: 
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact: 
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.

NEW YORK, February 1, 2018 /PRNewswire/ —

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce the closing of its previously announced public offering of an aggregate of 1,711,875 units consisting of one common and share and one warrant at a public offering price of $3.20 per unit for gross proceeds of $5.48 million.

Roth Capital Partners acted as lead placement agent and CIM Securities acted as co-lead placement agent for the offering.

The proceeds from the offering provide Q BioMed the required capital to execute on the launch of its non-opioid FDA approved Strontium Chloride 89 USP Injection (SR89), a therapeutic drug for the treatment of skeletal pain associated with metastatic cancers. In addition, the company will focus on the clinical planning and IND filing for a Phase 4 post-marketing study to expand the indication of the approved SR89, labeling it as chemotherapeutic (a cancer therapy) for skeletal metastases, significantly improving the revenue potential for the drug.

Additionally, this raise allows us to complete pre-IND studies and the filing of an IND for a pivotal phase ll/lll clinical program to test the efficacy of QBM-001. QBM-001 is a pro-drug for the treatment of young children with a rare autistic spectrum disorder that severely inhibits their ability to communicate. There are currently no therapeutic options for this desperate patient population of approximately 50,000 annually diagnosed children every year. This important trial could provide a desperately needed treatment to ameliorate the condition and other related modalities that cost the healthcare system $10 million per patient lifetime.  As a result, it represents a very significant multi-billion dollar opportunity.

We will also continue development work on our novel chemotherapeutic drug for liver cancer, a condition with very few therapeutic alternatives; as well as completion of optimization and pre-clinical testing of the first-in-class glaucoma drug Man-01 for the treatment of open angle glaucoma, a disease affecting more than 60,000,000 people around the world.

Denis Corin, Q BioMed Inc. CEO said, “This capital sets up a catalyst-rich year for us. We look forward to a productive year ahead as we start to meet the milestones and goals we set ourselves from the founding of the company in 2015.”

Q Biomed is a commercial stage biomedical acceleration and development company. We spent our first two years building a valuable portfolio of assets that we believe have significant upside based on our investment in their development. This year, the return on that investment of strategic resources should start to be realized as we advance those assets along their important commercial paths towards the patients that need them and economically, the billion dollar markets they represent.

Please visit http://www.qbiomed.com for more information and sign up to receive regular updates. Follow us on social media @QBioMed.

More information on the funding can be found on our form 8k filed with the SEC today.

A registration statement on Form S-1 (File No. 333-222008) relating to this offering was declared effective by the Securities and Exchange Commission (SEC) on January 12, 2018. The securities may be offered only by means of a prospectus. A copy of the final prospectus is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus also may be obtained from Roth Capital Partners, LLC, Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, at 800-678-9147 and rothecm@roth.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Q BioMed, Inc. 

Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements: 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
1-888-357-2435

SOURCE Q BioMed Inc.